and last week unveiling promising data for an oral version of the drug. Lilly has had an advantage over Novo until recently, as Trulicity matched Victoza’s blood sugar lowering, but needs to be ...
Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the ... from Eli Lilly’s once-weekly rival Trulicity (dulaglutide), tipped by EvaluatePharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback